cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Alkermes Plc
6 own
13 watching
Current Price
$24.27
$0.2
(0.83%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
4,823.6M
52-Week High
52-Week High
33.71000
52-Week Low
52-Week Low
22.01000
Average Volume
Average Volume
1.22M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization4,823.6M
icon52-Week High33.71000
icon52-Week Low22.01000
iconAverage Volume1.22M
iconDividend Yield--
iconP/E Ratio--
What does the Alkermes Plc do?
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Read More
How much money does Alkermes Plc make?
News & Events about Alkermes Plc.
PR Newswire
10 months ago
Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders PR Newswire DUBLIN, June 29, 2023 No Sarissa Nominees Elected by...
Accesswire
10 months ago
NORTHAMPTON, MA / ACCESSWIRE / June 27, 2023 / AlkermesA one-size-fits-all approach to mental health care does not work for everyone in the LGBTQ+ community. Each sub-community faces unique challenges. Check out these tips from NAMI if you or someone you care about is seeking LGBTQ+ competent...
Accesswire
10 months ago
NORTHAMPTON, MA / ACCESSWIRE / June 21, 2023 / Alkermes:This PrideMonth, Alkermes honors the resiliency of the LGBTQ+ community. We're committed to fighting the stigmas that may contribute to substance abuse and may act as barriers to receiving treatment. View additional multimedia and more ESG...
Business Wire
10 months ago
Sarissa Capital Management LP (Sarissa) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa has made a compelling case for change to the board of directors of Alkermes plc (NASDAQ: ALKS): We are pleased that ISS recognizes the...
Accesswire
10 months ago
NORTHAMPTON, MA / ACCESSWIRE / June 16, 2023 / AlkermesOn Monday we commemorate Juneteenth - also known as Freedom Day - the anniversary of the freeing of the last enslaved Black Americans, which took place on June 19th, 1865, more than two years after President Lincoln issued the Emancipation...
Frequently Asked Questions
Frequently Asked Questions
What is Alkermes Plc share price today?
plus_minus_icon
Can Indians buy Alkermes Plc shares?
plus_minus_icon
How can I buy Alkermes Plc shares from India?
plus_minus_icon
Can Fractional shares of Alkermes Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Alkermes Plc stocks?
plus_minus_icon
What is today’s traded volume of Alkermes Plc?
plus_minus_icon
What is today’s market capitalisation of Alkermes Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Alkermes Plc?
plus_minus_icon
What percentage is Alkermes Plc down from its 52-Week High?
plus_minus_icon
What percentage is Alkermes Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$24.27
$0.2
(0.83%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00